Find a Doctor or Practice Location

Are you a referring physician?
within
I am searching for a
Reset Form
Priti Lal, MD

Priti Lal, MD Physician

Associate Professor of Pathology and Laboratory Medicine at the Hospital of the University of Pennsylvania

Dr. Lal is a Penn Medicine employed physician.

Clinical Specialties

Specialty:

  • Pathology and Laboratory Medicine

Programs & Centers:

Board Certification:

  • Pathology - Anatomic Pathology, 2010

Description of Clinical Expertise

GU Pathology. Cardiovascular and renal transplantation pathology.

Practice Locations and Appointments

Insurance Accepted

  • Aetna US Healthcare
  • Cigna
  • Cigna HealthSpring
  • Devon Health Services (Americare)
  • Gateway Health Plan
  • Geisinger Health Plan
  • HealthAmerica / HealthAssurance, a Coventry Plan
  • HealthPartners
  • HealthPartners Medicare
  • HealthSmart
  • Highmark Blue Shield
  • Horizon Blue Cross Blue Shield of New Jersey
  • Humana / Choicecare
  • Independence Blue Cross (Keystone East)
  • Intergroup
  • Keystone First
  • Multiplan
  • NJ Medicaid
  • NJ Qualcare
  • Oxford Health Plan
  • PA Medicaid
  • PA Medicare
  • Preferred Care
  • Preferred Health Care/LGH
  • Rail Road Medicare / Palmetto GBA
  • Tricare
  • United Healthcare
  • UnitedHealthcare Community Plan
  • US Family Health Plan

Education and Training

Medical School: Maulana Azad Medical College University of Delhi
Fellowship: National Institutes of Health
Residency: University of Medicine and Dentistry of New Jersey
Fellowship: Armed Forces Institute
Fellowship: Memorial Sloan-Kettering Cancer Center

Memberships

AACR, National College of American Pathologists, National ISUP, International Pennsylvania Association of Pathologists, Local

Hospital Affiliation

Dr. Lal is a Penn Medicine employed physician.

Hospital Privileges:

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
  • Penn Presbyterian Medical Center: Has privileges to treat patients in the hospital.
  • Pennsylvania Hospital: Has privileges to treat patients in the hospital.

Research

Description of Research Expertise:

Application of high through-put technology to gain insights into the biology of human cancers, with special interest in GU cancers.

Selected Publications:

Priti Lal, Kosj Yamoah, Amy Ziober, Amy Walker, Wenting Zhou, Elaine Spangler, Charnita Zeigler-Johnson, Michael Feldman, Timothy R. Rebbeck.: Racial Differences in the Distribution of Prostate Tumor Biomarkers and Treatment Failure: The SCORE Study Clinical Cancer Research : 2015.

Kosj Yamoah, Michael Hiroshi Johnson, Voleak Choeurng, Kasra Yousefi, Zaid Haddad, Robert Benjamin Den, Priti Lal, Michael D Feldman, Adam Dicker, Eric A. Klein, Elai Davicioni, Timothy R. Rebbeck, Edward M. Schaeffer: A novel biomarker signature which may predict aggressive disease in African-American men with prostate cancer. Journal of Clinical oncology : 2015.

Kosj Yamoah, M.D., Ph.D.; Amy Walker, M.S.; Elaine Spangler, M.S.; Charnita M Zeigler-Johnson, M.D., Ph.D.; Bruce Malkowicz, M.D.; David I Lee, M.D.; Adam P Dicker, M.D., Ph.D.; Priti Lal, M.D.: African-American race is a predictor of seminal vesicle invasion following radical prostatectomy. Clinical Genitorurinary Cancer : 2014.

Priti Lal, MD: Chapter 39: Prostate. Diagnostic molecular pathology. Diagnostic Molecular pathology, 2nd edition : 2015.

David J. Vaughn, MD,Wei-Ting Hwang, PhD,Priti Lal, MD,Mark Rosen, MD Maryann Gallagher, Peter J. O’Dwyer, MD: Phase II Trial of the CDK 4/6 Inhibitor Palbociclib in Patients with Retinoblastoma Protein Expressing Germ Cell Tumors Cancer : 2014.

Stephen Michael Keefe, Daniel Heitjan, Meliessa Hennessey, Janelle Robinson, Kristine Mykulowicz, Amy Marshall, Orvar Gunnarsson, Ronac Mamtani, David J. Vaughn, Jean H. Hoffman-Censits, Katherine L. Nathanson, Priti Lal, Daniel A. Pryma, Scott Eliasof, Edward Graeme Garmey, Roger B. Cohen, Naomi B. Haas;: Interim results of a phase 1b/2a study evaluating the nano pharmaceutical CRLX101 with bevacizumab (bev) in the treatment of patients (pts) with refractory metastatic renal cell carcinoma (mRCC). ASCO : 2014.

Mathew LK, Lee SS, Skuli N, Rao S, Keith B, Nathanson KL, Lal P, Simon MC: Restricted Expression of miR-30c-2-3p and miR-30a-3p in Clear Cell Renal Cell Carcinomas Enhances HIF2a Activity. Cancer Discov 4 (1): 53-60,2014.

Priti Lal, MD: Applications of OCT 4 in Diagnostic immunohistochemistry Leong's Manual of Diagnostic Antibodies for Immunohistology 3rd edition : 2014.

Priti Lal, MD: Application of GATA 3 in diagnostic immunohistochemistry Leong's Manual of Diagnostic Antibodies for Immunohistology 3rd edition : 2014.

Priti Lal, MD: Application of SALL4 in diagnostic immunohistochemistry Leong's Manual of Diagnostic Antibodies for Immunohistology 3rd edition : 2014.

Academic Contact Info

Department of Pathology and Laboratory Medicine
Hospital of the University of Pennsylvania
6 Founders Pavilion
3400 Spruce Street

Philadelphia, PA 19104-4283
Phone: (215) 662-6505

Related Links